AcelRx Pharmaceuticals (United States)

Overview

Compare with GT Biopharma, Inc., Rafael Holdings, Inc. or IMPACT BIOMEDICAL INC., or pick any stock.

• TickerTLPH on Nasdaq¹
• IndustryPharmaceutical Preparations¹
• HeadquartersRedwood City¹
• Websitewww.acelrx.com
• Incorporated inDE⁴
• Business address1850 Gateway Drive, Suite 175, San Mateo, Ca 94404⁴
• Filer categoryNon-accelerated filer, Smaller reporting company⁴
• Legal formCorporation

See how the biggest companies compare on our leaderboards

We are a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings.⁵ From its latest annual report

Corporate structure

AcelRx Pharmaceuticals (United States) sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.

Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.

What it owns

What AcelRx Pharmaceuticals (United States) reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.

Investments

Intangibles and goodwill

Properties, in its own words

We lease approximately 4,012 square feet of office space in San Mateo, California under a lease agreement that expires on August 31, 2027. We believe that our facilities are adequate to meet our current needs.

Item 2 of the 10-K filed Mar 23, 2026.⁵

Leadership

Who has led AcelRx Pharmaceuticals (United States), and when. Pick a name to see everywhere that person has worked.

• Chief executive officerHoward B. Rosen Apr 3, 2015 to Feb 17, 2017¹⁴
• Chief financial officerRaffi Asadorian Aug 17, 2017 to now¹⁵
• Chief financial officerTimothy E. Morris Apr 9, 2014 to Feb 9, 2017¹⁶
• Chief financial officerJames H. Welch Feb 10, 2011 to Feb 6, 2014¹⁷

Named in SEC Form D filings

People the company listed in its private-offering notices.

• Executive Officer, DirectorVincent J Angotti named Jan 24, 2022 to Sep 15, 2025³⁹
• DirectorJill P Broadfoot named Jan 24, 2022 to Sep 15, 2025³⁹

Former names

• ACELRX PHARMACEUTICALS INCFeb 19, 2008 to Dec 14, 2023⁴

Timeline

1. Aug 12, 20268-K Results of operations⁴⁰
2. Jun 23, 20268-K Executive or director change; Shareholder vote⁴¹
3. May 13, 20268-K Results of operations⁴²
4. Mar 23, 20268-K Results of operations⁴³
5. Mar 16, 20268-K Unregistered sale of shares⁴⁴
6. Mar 13, 20268-K Listing notice or transfer⁴⁵
7. Nov 12, 20258-K Results of operations⁴⁶
8. Oct 24, 20258-K Executive or director change; Shareholder vote⁴⁷
9. Oct 22, 20258-K Unregistered sale of shares; Other events⁴⁸
10. Oct 16, 20258-K Executive or director change⁴⁹
11. Sep 10, 20258-K Entered a material agreement; Unregistered sale of shares⁵⁰
12. Aug 14, 20258-K Results of operations⁵¹
13. Apr 3, 2015New chief executive Howard B. Rosen becomes CEO¹⁴
14. 2005Founded Founded¹

Calendar

Coming up

1. Nov 11, 2026Reports results for the quarter ending Sep/2026 A year earlier it reported ($0.11) a share, on Nov 12, 2025.⁵²

When it reported results

1. Aug 12, 2026Reported quarterly or annual results⁴⁰
2. May 13, 2026Reported quarterly or annual results⁴²
3. Mar 23, 2026Reported quarterly or annual results⁴³
4. Nov 12, 2025Reported quarterly or annual results⁴⁶
5. Aug 14, 2025Reported quarterly or annual results⁵¹
6. May 14, 2025Reported quarterly or annual results⁵³
7. Mar 31, 2025Reported quarterly or annual results⁵⁴
8. Nov 13, 2024Reported quarterly or annual results⁵⁵

Upcoming dates from Nasdaq's calendar; past results from the company's 8-K filings (Item 2.02). The full markets calendar

Filings

306 filings to the SEC since October 2021: 8 annual reports, 15 quarterly reports, 67 major events, 115 insider forms, 21 large holders, 6 private raises, 74 other. The latest 20:

1. Aug 12, 2026SCHEDULE 13G/A EDGAR
2. Aug 12, 2026S-8 EDGAR
3. Aug 12, 202610-Q EDGAR
4. Aug 12, 20268-K EDGAR
5. Jun 24, 20264 EDGAR
6. Jun 24, 20264 EDGAR
7. Jun 24, 20264 EDGAR
8. Jun 24, 20264 EDGAR
9. Jun 24, 20264 EDGAR
10. Jun 24, 20264 EDGAR
11. Jun 24, 20264 EDGAR
12. Jun 23, 20268-K EDGAR
13. May 21, 20264 EDGAR
14. May 15, 2026SCHEDULE 13G/A EDGAR
15. May 13, 202610-Q EDGAR
16. May 13, 20268-K EDGAR
17. May 12, 2026SCHEDULE 13G/A EDGAR
18. Apr 29, 2026DEFA14A EDGAR
19. Apr 29, 2026DEF 14A EDGAR
20. Apr 3, 20264 EDGAR

Every filing from the last five years, summarized. The full record is on SEC EDGAR.

Insider trades

20 open-market trades by officers, directors and large owners since October 2021: 17 buys and 3 sales. Grants, option exercises and gifts are left out.

From Forms 4 filed with the SEC.

Major holders

Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.

• Rosalind Advisors, Inc.SCHEDULE 13G/A, 5 filings Apr 11, 2025 to Aug 12, 2026⁵⁶
• Laurence W. LyttonSCHEDULE 13G/A, 3 filings Sep 16, 2025 to May 15, 2026⁵⁷
• Orin HirschmanSCHEDULE 13G/A, 2 filings Nov 10, 2025 to Jan 30, 2026⁵⁸
• CorMedix Inc.SCHEDULE 13D, 1 filing Sep 12, 2025⁵⁹
• Rock Springs Capital Management LPSCHEDULE 13G, 1 filing Sep 12, 2025⁶⁰
• Nantahala Capital Management, LLCSCHEDULE 13D/A, 3 filings Jan 23, 2024 to Apr 3, 2025⁶¹
• ARMISTICE CAPITAL, LLCSC 13G/A, 3 filings Feb 15, 2022 to Feb 14, 2024⁶²
• Lind Global Fund II LPSC 13G/A, 2 filings Aug 1, 2023 to Feb 13, 2024⁶³
• BML Investment Partners, L.P.SC 13G/A, 1 filing Jan 27, 2022⁶⁴

Executive pay

What the company paid its top executives, from the summary compensation table in its proxy statement. Total pay includes salary, bonus, stock and option awards and other pay, as the company valued them.

Money raised

Private offerings the company reported to the SEC on Form D.

1. Sep 10, 2025Raised $17 million in a private offering of equity Form D: $29 million offered in all Form D
2. Apr 2, 2025Raised $4.9 million in a private offering of equity Form D: $15 million offered in all Form D
3. Jan 22, 2024Raised $6 million in a private offering of securities Form D: 6 investors so far Form D
4. Jul 17, 2023Raised $10 million in a private offering of equity Form D: 10 investors so far Form D
5. Aug 3, 2022Raised $629,958 in a private offering of equity Form D: 1 investor so far Form D
6. Jan 7, 2022Raised $5.2 million in a private offering of equity Form D: $6 million offered in all Form D

Held by these funds

The largest holders among investment managers' 13F reports for the quarter ending Jun 30, 2026, the top 25 of 49. Change is in shares since the quarter before.

13F reports cover disclosed long positions in U.S. stocks only.

SEC filer profile

How AcelRx Pharmaceuticals (United States) is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.

• Name on EDGARTALPHERA, INC.²
• CIK0001427925
• Employer ID (EIN)41-2193603⁵
• Filer statusNon-accelerated filer not an emerging growth company; a smaller reporting company; not a shell company⁵
• Incorporated inDelaware⁵
• Fiscal year endsDecember 31²
• Industry code (SIC)2834 Pharmaceutical Preparations²
• SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance²
• Business address1850 Gateway Drive, Suite 175, San Mateo, CA 94404²
• Phone650-216-3500²
• Shares outstanding51,905,796 as of Aug 6, 2026¹³
• Public float$8.3M as of Jun 30, 2025⁵
• AuditorBPM LLP, Walnut Creek, California PCAOB ID 207; no auditor attestation of internal control over financial reporting⁵
• On EDGAR sinceFeb 19, 2008²
• Filings962 in all: 4 (368), 8-K (229), 10-Q (47), 3 (30), CORRESP (20), EFFECT (18), S-8 (17), 10-K (16)²
  All 44 form types

  424B5 (16), DEF 14A (16), UPLOAD (16), DEFA14A (15), SC 13G/A (15), S-3 (14), CT ORDER (12), 425 (11), SC 13G (11), D (10), 424B7 (9), SC 13D/A (8), SCHEDULE 13G/A (7), 10-K/A (6), S-1/A (6), 4/A (5), 8-K/A (4), PRE 14A (4), SC 13D (4), SCHEDULE 13G (4), 144 (3), 424B3 (2), 424B4 (2), ARS (2), S-1 (2), S-3/A (2), SCHEDULE 13D/A (2), 5 (1), 8-A12B (1), CERTNAS (1), POS AM (1), REGDEX (1), S-3MEF (1), S-4 (1), S-4/A (1), SCHEDULE 13D (1)

• Latest filingsAnnual report (10-K) Mar 23, 2026
  Quarterly report (10-Q) Aug 12, 2026
  Proxy statement (DEF 14A) Apr 29, 2026
  Latest 8-K (8-K) Aug 12, 2026

Securities registered for trading

From the cover page of the 10-K filed Mar 23, 2026 (Section 12(b) of the Exchange Act).⁵

Risk factors and legal proceedings

The risks AcelRx Pharmaceuticals (United States) names in Item 1A of its 10-K filed Mar 23, 2026: 47 risks under these headings, as written.⁵

• Our operations and financial results are subject to various risks and uncertainties. You should carefully consider the risks described below, together with all of the other information in this report, including our financial statements and notes thereto. If any of the following risks actually materialize, our business, financial condition, results of operations, liquidity, and future prospects could be materially harmed, the price of our common stock could decline, and you could lose part or all of your investment.
• Risks Related to Our Financial Condition and Need for Additional Capital
• We have incurred significant losses since our inception and anticipate that we will continue to incur losses in the future.
• We require additional capital and may be unable to raise such capital, which would force us to delay, reduce or eliminate our product development programs and commercialization efforts and could cause us to be unable to continue to operate as a going concern and cease operations.
• To fund our operations and capital requirements, we may sell additional equity securities, which may result in dilution to our stockholders, or debt securities, or enter into a new debt facility which may impose restrictions on our business.
• We have not yet generated significant product revenue and may never be profitable.
• Risks Related to Drug Development and Commercialization
• We may fail to realize the benefits expected from our acquisition of Lowell, which could adversely affect our stock price.
• Delays in clinical trials are common and have many causes, and any delay could result in increased costs to us and jeopardize or delay our ability to obtain regulatory approval and commence product sales.
• Our development efforts might not generate successful product candidates.
• If clinical trials of our product candidates fail to demonstrate safety and efficacy to the satisfaction of regulatory authorities or do not otherwise produce positive results, we may incur additional costs or experience delays in completing, or ultimately be unable to complete, the development and commercialization of our product candidates.
• If we experience delays or difficulties in enrolling patients in clinical trials, our receipt of necessary regulatory approvals could be delayed or prevented.

Legal proceedings

From time to time, we may be involved in legal proceedings relating to intellectual property, commercial, employment and other matters arising in the ordinary course of business. Such matters are subject to uncertainty and there can be no assurance that such legal proceedings will not have a material adverse effect on our business, results of operations, financial position or cash flows. Please see Note 7, “Commitments and Contingencies—Litigation” to our consolidated financial statements in this Annual Report on Form 10-K for additional information with respect to our legal proceedings.

The opening of Item 3, Legal Proceedings.⁵

Links

• Websitewww.acelrx.com¹
• WikidataQ30270758
• SEC EDGARCIK 1427925